Can Assyro replace Pharmaprojects' pipeline database?

No. Assyro researches supported public records and does not provide Citeline's analyst-curated drug-pipeline dataset or proprietary enrichment.

Are Pharmaprojects and Trialtrove the same application?

They are separately named offerings: pipeline intelligence and trial intelligence respectively. Confirm both applications, editions and licensed fields when both are required.

Does a trial result establish asset development status?

Not by itself. Reconcile asset aliases, indication, sponsor and dated evidence. One study's status should not be silently promoted to a drug-wide conclusion.

Does Trialtrove include all Sitetrove or '+' capabilities?

Do not assume it. Current Citeline pages separately describe related site/investigator and enhanced offerings. Obtain the exact inclusion and data-rights matrix.

Comparison/Updated October 2026

Assyro Intelligence vs Citeline Pharmaprojects and Trialtrove

Compare the dataset and entity model behind a landscape—not just how quickly a tool answers a trial question.

Assyro Intelligence

by Assyro AI

Public-source research with record citations and scheduled watches.

Assyro Intelligence

Cited public trialsRegulatory contextScheduled watchesFree to start

Citeline Pharmaprojects and Trialtrove

Curated drug-pipeline and clinical-trial intelligence

Separately named pipeline and trial applications with expert curation and analyst access.

Curated pipelineTrial benchmarkingAnalyst accessApplication-specific scope

The verdict

Evaluate Assyro Intelligence for cited questions about supported public trial, regulatory, literature and disclosed competitor records. Evaluate Pharmaprojects for curated drug-development landscapes and Trialtrove for curated trial benchmarking. Assyro does not replace Citeline's analyst-curated pipeline or proprietary enrichment. Specify the applications and editions: Sitetrove and the '+' offerings have separately described scope and should not be silently included in a Pharmaprojects/Trialtrove proposal.

Manually written by Assyro AI, a compared vendor. Current Pharmaprojects and Trialtrove pages checked October 13, 2026, including analyst and related-application scope. No independent dataset-completeness or answer-speed benchmark was performed.

Match the intelligence layer to the clinical decision

Specific record lookup, asset landscapes and protocol benchmarking are different purchases.

Research versus curated datasets
Task	Assyro	Citeline
Verify a public trial fact	Cited registry research	Qualify original-source links
Curated asset landscape	Outside proprietary scope	Pharmaprojects
Trial benchmarking	Available public fields	Trialtrove
Site performance	Outside proprietary scope	Qualify Sitetrove/+ scope

Verify a public trial fact
Assyro
Cited registry research
Citeline
Qualify original-source links
Curated asset landscape
Assyro
Outside proprietary scope
Citeline
Pharmaprojects
Trial benchmarking
Assyro
Available public fields
Citeline
Trialtrove
Site performance
Assyro
Outside proprietary scope
Citeline
Qualify Sitetrove/+ scope

[1][2][3]

Citations do not establish landscape completeness

A cited answer can correctly summarize the records retrieved while missing an asset, alias or unpublished update. Define the intended population, source availability and entity rules before asking either tool for a complete landscape.

Use Assyro for supported public evidence questions and select the curated product when its normalized dataset and analyst layer are necessary. Keep undisclosed or unavailable information visible as a gap.

Feature by feature

Published capabilities, related applications and evidence still to request.

Trial research
Assyro Intelligence
Supported public registries with record citations[3]
Citeline
Trialtrove curated trial intelligence[2]
Curated development pipeline
Assyro Intelligence
No proprietary pipeline database[3]
Citeline
Pharmaprojects drug-development landscape[1]
Protocol/trial benchmarking
Assyro Intelligence
Public-record comparisons; no curated benchmark dataset[3]
Citeline
Trialtrove design and outcome benchmarking scope[2]
Analyst service
Assyro Intelligence
No subscribed Ask-the-Analyst service[3]
Citeline
Analyst access described; confirm entitlement[1][2]
Site/investigator performance
Assyro Intelligence
No proprietary site-performance dataset[3]
Citeline
Related Sitetrove/+ scope requires explicit inclusion[2]
Commercial terms
Assyro Intelligence
Free start; custom team pricing with unlimited users[3][4]
Citeline
Request application/edition, data and export terms[1][2]

Assyro Intelligence and Citeline Pharmaprojects and Trialtrove: feature comparison
Capability	Assyro Intelligence	Citeline
Trial research	Supported public registries with record citations[3]	Trialtrove curated trial intelligence[2]
Curated development pipeline	No proprietary pipeline database[3]	Pharmaprojects drug-development landscape[1]
Protocol/trial benchmarking	Public-record comparisons; no curated benchmark dataset[3]	Trialtrove design and outcome benchmarking scope[2]
Analyst service	No subscribed Ask-the-Analyst service[3]	Analyst access described; confirm entitlement[1][2]
Site/investigator performance	No proprietary site-performance dataset[3]	Related Sitetrove/+ scope requires explicit inclusion[2]
Commercial terms	Free start; custom team pricing with unlimited users[3][4]	Request application/edition, data and export terms[1][2]

Product details and recommendations reflect publicly available information and our own assessment as of October 2026, provided for comparison. Citeline Pharmaprojects and Trialtrove is a product of Citeline; trademarks belong to their respective owners.

Which one should you choose?

Choose Assyro Intelligence if

You need to find and verify specific public trial/regulatory facts.
Your team owns entity reconciliation and interpretation.
An identified-source watch meets the monitoring requirement.

Choose Citeline if

A curated drug pipeline is the required decision input.
Trial-design benchmarking and enriched trial records are central.
Analyst support or separately scoped site-performance data belongs in the purchase.

The detailed comparison

Is the trial the same as the drug asset?

Assyro Intelligence

Retain registry identifiers and distinguish one trial from an asset, indication or sponsor. A trial status does not establish the asset's overall development status or commercial prospects.

Citeline

Test the curated relationships between asset, aliases, sponsor, indication and trials. Ask how a licensing change or conflicting public status is reconciled, and inspect the date and evidence behind the record.

[1][2][3]

What does the proposed benchmark actually measure?

Assyro Intelligence

Define the population and available public fields before comparing studies. Mark missing dates or outcomes; do not treat them as zero values.

Citeline

Use the intended Trialtrove fields and filters, document inclusion/exclusion rules and inspect original evidence. Qualify any site/investigator performance requirement in the named application instead of assuming it from a trial database.

[2]

Price the data and analyst scope, not just search access

Request application/edition, user, dataset fields, analyst service, export/API and retention terms. Include any required Sitetrove/+ scope explicitly; a trial licence cannot price an entire portfolio.

Match Assyro only to the supported public-research portion. Cost entity reconciliation, clinical review, landscape maintenance and watch triage. No matched quote or measured analyst-effort comparison supports a savings claim.

[1][2][4]

An asset-and-trial evidence worksheet

Record asset aliases, indication, sponsor, registry IDs, status/date, source, missing fields and reviewer disposition.

Alias collision

Use an asset with multiple names and verify that distinct trials and indications are not merged incorrectly.

Conflicting status

Present a registry update and a sponsor disclosure with differing dates; retain both and explain the chosen conclusion.

Benchmark population

Define inclusion rules, reproduce a filtered set and inspect missing endpoints or enrollment dates.

Watch and retention

Track one identified trial/asset, verify the changed evidence and export only what the licence permits.

Where Citeline is stronger

No tool wins on everything. Here is where Citeline is the better choice today.

A curated pipeline data model beyond registry-only research.
Dedicated trial-design and outcome benchmarking functions.
Published analyst access for questions requiring context or record clarification.

Adopting Assyro Intelligence

Keep curated landscape and public-record research as separate evidence layers where both are needed. Do not transfer licensed Citeline datasets or analyst responses into another system without approved rights. No direct connector is established here.

1Inventory landscapes, filters, asset aliases, registry identifiers and licensed exports.
2Check data reuse, downstream processing and retention rights.
3Define an overlapping public-question sample with inclusion rules.
4Reconcile entities, status dates and source gaps with clinical/CI reviewers.
5Assign watch ownership and preserve the curated dataset for decisions that require it.

Sources and evidence

Product documents establish published scope. Evaluation scenarios and recommendations are Assyro's analysis. Confirm availability, configuration and contract scope with each vendor.

Citeline Pharmaprojects
Curated pipeline, landscapes, alerts and analyst service; checked October 13, 2026; no revision displayed
Citeline Trialtrove
Curated trials, benchmarking, analyst access and separately linked Sitetrove/+ scope; checked October 13, 2026
Assyro Intelligence product scope
Published product definition and capability scope; checked October 13, 2026; related applications require their own quoted scope
Assyro pricing
Published custom pricing and unlimited users on every plan; checked October 13, 2026; no competitor price advantage inferred